Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating diseased tissues in a patient, comprising:

(A) administering to said patient a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

(B) optionally, administering to said patient a clearing composition, and allowing said composition to clear non-localized antibodies or antibody fragments from circulation;

(C) administering to said patient a first targetable conjugate which comprises a carrier portion and one or more conjugated enzymes, wherein said carrier portion comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment; and

(D) administering to said patient

(1) ~~a prodrug, when said enzyme is capable of converting said prodrug to a drug at the targeted tissue; or~~

~~(2)~~ a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the targeted tissue, or

(~~3~~ 2) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the targeted tissue, or

([[4]] 3) a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the targeted tissue.

2-11. (Canceled).

12. (Original) The method of claim 1, wherein said at least one arm that specifically binds a targeted tissue is a monoclonal antibody or a fragment of a monoclonal antibody.

13. (Original) The method of claim 1, wherein said at least one other arm that specifically binds a targetable conjugate is a monoclonal antibody or a fragment of a monoclonal antibody.

14. (Original) The method of claim 1, wherein said at least one arm that specifically binds a targeted tissue is a humanized antibody or a fragment of a humanized antibody.

15. (Original) The method of claim 1, wherein said at least one other arm that specifically binds a targetable conjugate is a humanized antibody or a fragment of a humanized antibody.

16. (Previously presented) The method of claim 1, wherein said first or second targetable conjugate comprises a peptide to which said at least one other arm of said bi-specific antibody binds.

17. (Previously presented) The method of claim 1, wherein said second targetable conjugate comprises a carrier portion comprising a carbohydrate.

18. (Previously presented) The method of claim 1, wherein said first or second targetable conjugate comprises one or more haptens to which said at least one other arm of said bi-specific antibody binds.

19. (Previously presented) The method of claim 1, wherein said first or second targetable conjugate comprises one or more chelators or metal-chelate complexes to which said at least one other arm of said bi-specific antibody binds.

20-29. (Canceled).

30. (Currently amended) A kit useful for treating diseased tissues in a patient comprising:

(A) a bi-specific antibody or antibody fragment having at least one arm that specifically binds a targeted tissue and at least one other arm that specifically binds a targetable conjugate;

(B) a first targetable conjugate which comprises a carrier portion and one or more conjugated enzymes, wherein said carrier portion comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment;

(C) optionally, a clearing composition useful for clearing non-localized antibodies and antibody fragments; and

(D) (1) ~~a prodrug, when said enzyme is capable of converting said prodrug to a drug at the targeted tissue; or~~

~~(2)~~ a drug which is capable of being detoxified in said patient to form an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified

intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the target site, or

(~~3~~ 2) a prodrug which is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, when said enzyme is capable of reconverting said detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the targeted tissue, or

([[4]] 3) a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and a prodrug, when said enzyme is capable of converting said prodrug to a drug at the targeted tissue.

31-51. (Canceled).

52. (Previously presented) The method of claim 1, wherein (D) comprises administering a prodrug that is activated in said patient through natural processes and is subject to detoxification by conversion to an intermediate of lower toxicity, and said enzyme is capable of reconverting the detoxified intermediate to a toxic form, and, therefore, of increasing the toxicity of said drug at the targeted tissue.

53. (Previously presented) The method of claim 1, further comprising, when said first targetable conjugate additionally comprises a prodrug, administering a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.

54. (Previously presented) The kit of claim 30, further comprising, when said first targetable conjugate additionally comprises a prodrug, a second targetable conjugate which comprises a carrier portion which comprises or bears at least one epitope recognizable by said at least one other arm of said bi-specific antibody or antibody fragment, and an enzyme capable of converting said prodrug to a drug or of reconverting a detoxified intermediate of said drug to a toxic form.

55-56. (Canceled).